| 研究所： | | | | | --- | --- | --- | --- | | 证券分析师： | | 马川琪 | S0350523050001 | | | | | macq@ghzq.com.cn | | 联系人 | ： | 丁婧欣 | S0350124040002 | | | | dingjx@ghzq.com.cn | | 2025 年 07 月 22 日 公司研究 评级：买入(维持) [Table_Title] "内生+外延"双轮驱动，25H1 净利同比增超 35% ——美丽田园医疗健康（02373）动态研究 最近一年走势 | 相对恒生指数表现 | | | 2025/07/21 | | --- | --- | --- | --- | | 表现 | 1M | 3M | 12M | | 美丽田园医 | 36.5% | 81.4% | 91.8% | | 疗健康 | | | | | 恒生指数 | 6.2% | 16.8% | 43.5% | 相关报告 | 市场数据 | 2025/07/21 | | --- | --- | | 当前价格（港元） | 30.30 | | 52 周价格区间（港元） | 15. ...

证券代码：300838 证券简称：浙江力诺 浙江力诺流体控制科技股份有限公司 投资者关系活动记录表 | | 特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访  业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | 其他（请文字说明其他活动内容） | | 参与单位名称及 | 浙江力诺 2024 年度业绩说明会采用网络远程方式进行，面向全 | | 人员姓名 | 体投资者 | | 时间 | 年 月 日（周一）15:00~17:00 2025 5 12 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采 | | | 用网络远程的方式召开业绩说明会 | | | 董事长兼总经理：陈晓宇 | | 上市公司接待人 | 副总经理、董事会秘书：冯辉彬 | | 员姓名 | 副总经理、财务总监：李雪梅 | | | 独立董事：黄志雄 | | | 1、你们行业本期整体业绩怎么样？你们跟其他公司比如何？ | | | 答：尊敬的投资者，您好！本期公司整体趋势与同行业基本一致。 | | | 公司因受多晶硅及锂 ...

Core Viewpoint - In Q1 2025, the company reported a revenue of 1.184 billion yuan, a year-on-year decrease of 7.03%, while achieving a net profit attributable to shareholders of 285 million yuan, an increase of 5.91% [1] Group 1: Financial Performance - The company's Q1 2025 revenue breakdown includes 885 million yuan from the OTC segment (down 12.12% YoY), 187 million yuan from the prescription drug segment (up 23.68% YoY), and 111 million yuan from the health segment (up 0.59% YoY) [1] - The gross profit margin and net profit margin for Q1 2025 were 68.21% and 24.06%, respectively, reflecting increases of 1.20 percentage points and 2.94 percentage points YoY [1] Group 2: Cost Management - The company's expense ratios for sales, management, R&D, and financial costs in Q1 2025 were 33.80%, 4.51%, 2.28%, and -1.49%, showing changes of -1.79, +1.31, -0.07, and +0.20 percentage points YoY, respectively [2] Group 3: Future Outlook - The company is expected to achieve revenues of 4.9 billion yuan, 5.542 billion yuan, and 6.224 billion yuan from 2025 to 2027, with year-on-year growth rates of 10%, 13%, and 12% [2] - The projected net profits attributable to shareholders for the same period are 890 million yuan, 1.028 billion yuan, and 1.172 billion yuan, with growth rates of 13%, 16%, and 14% [2] - The company maintains a "buy" rating with projected PE valuations of 16, 14, and 12 times for 2025, 2026, and 2027, respectively [2]

Core Viewpoint - Shanghai ZhiChun Clean System Technology Co., Ltd. (hereinafter referred to as "ZhiChun Technology") has reported a significant decline in net profit for 2024, despite a revenue increase, highlighting the challenges faced in the semiconductor equipment industry [1][2]. Financial Performance - In 2024, ZhiChun Technology achieved operating revenue of 3.605 billion yuan, a year-on-year increase of 14.40% [1] - The net profit attributable to the parent company was 23.5975 million yuan, a decline of over 90% year-on-year [2] - The company reported a shift from profit to loss in net profit after deducting non-recurring gains and losses [1] - In Q1 2025, ZhiChun Technology's revenue was 728 million yuan, down 10.32% year-on-year, with a net profit of 19.0161 million yuan, a decrease of 70.09% [3] Market Dynamics - In 2024, 84.55% of new orders came from the integrated circuit industry, primarily from leading users such as SMIC and Shanghai Huali [2] - The company faced increased competition in the semiconductor wet process equipment sector, which has a relatively low technical threshold and high domestic production rates [2] Strategic Initiatives - ZhiChun Technology plans to acquire 83.78% of Guizhou Weidun Crystal Phosphorus Electronic Materials Co., Ltd. to enhance its competitiveness in the semiconductor materials sector [1][4] - The acquisition aims to integrate high-purity electronic materials into ZhiChun Technology's business, improving its service offerings and core competitiveness [4] - The company anticipates new orders between 5.5 billion and 6 billion yuan for 2025, with a focus on high-end cleaning equipment [4] Ongoing Transactions - As of now, the audit, evaluation, and due diligence for the acquisition of Weidun Crystal Phosphorus are in progress, with further board meetings planned to discuss the transaction [5] - The acquisition is seen as a way to quickly integrate resources and optimize business layout, although it may face challenges such as financial risks and integration difficulties [5]

制图：佘诗婕 星标 ★ IPO日报 精彩文章第一时间推送 4月17日，深圳光韵达光电科技股份有限公司（300227.SZ）（下称"光韵达"、"上市公司"）股价以8.23元收盘，上涨5.51%。 4月16日晚间，国内激光制造龙头光韵达发布公告，拟以现金不超过6.5亿元收购深圳市亿联无限科技股份有限公司（下称"亿联无限"、"标的公 司"）100%股份。 交易双方已签署《股份转让意向协议书》，最终收购比例将协商确定，预计不构成关联交易或重大资产重组。 此次收购标志着，光韵达从激光智能制造向网络通信设备制造领域的战略性延伸，旨在完成电子制造产业链的上下游整合，并拓展海外市场。 增收不增利 据悉，光韵达是国内激光智能制造解决方案的龙头企业，业务涵盖SMT精密模板、3D打印、智能检测设备等领域，长期服务于华为、富士康等头部 客户。 公司近年来通过"内生+外延"战略持续扩张，不过从业绩层面来看，上市公司已经连续四年出现增收不增利的情况。 2020年至2024年，上市公司营业收入一路上涨， 由8.87亿元持续上涨至2024年的11.18亿元，增幅为26%；归母净利润却一路下滑，由2020年 的1.30亿元下滑至2023年的0 ...

星标 ★ IPO日报 精彩文章第一时间推送 4月17日，深圳光韵达光电科技股份有限公司（300227.SZ）（下称"光韵达"、"上市公司"）股价以8.23元收盘，上涨5.51%。 4月16日晚间，国内激光制造龙头光韵达发布公告，拟以现金不超过6.5亿元收购深圳市亿联无限科技股份有限公司（下称"亿联无限"、"标的公 司"）100%股份。 交易双方已签署《股份转让意向协议书》，最终收购比例将协商确定，预计不构成关联交易或重大资产重组。 此次收购标志着，光韵达从激光智能制造向网络通信设备制造领域的战略性延伸，旨在完成电子制造产业链的上下游整合，并拓展海外市场。 制图：李昕 同期，上市公司产品毛利率由2020年的42.45%一路下滑至2024年29.38%。 制图：李昕 制图：佘诗婕 增收不增利 据悉，光韵达是国内激光智能制造解决方案的龙头企业，业务涵盖SMT精密模板、3D打印、智能检测设备等领域，长期服务于华为、富士康等头部 客户。 公司近年来通过"内生+外延"战略持续扩张，不过从业绩层面来看，上市公司已经连续四年出现增收不增利的情况。 2020年至2024年，上市公司营业收入一路上涨， 由8.87亿元持续上涨至2 ...

Core Viewpoint - The company reported a steady growth in revenue and net profit for 2024 despite industry pressures, with a revenue of 3.03 billion and a net profit of 1.96 billion, reflecting year-on-year increases of 5.4% and 5.3% respectively [2][3] Revenue and Profit Analysis - In Q4 2024, the company's revenue was 650 million, showing a year-on-year decline of 7.0%, while the net profit was 370 million, down 15.5% year-on-year [2] - The revenue from solution products and gel products for 2024 was 1.74 billion and 1.22 billion respectively, with year-on-year growth of 4.4% and 5.0% [3] Product Performance - The sales volume for solution products was 634.6 thousand units, up 23.4% year-on-year, while gel products saw a decline in sales volume to 89.4 thousand units, down 11.2% [3] - The average price of solution products decreased due to a shift in product mix, while the average price of gel products increased due to a higher proportion of high-margin products [3] Profitability Metrics - The company's gross margin for 2024 was 94.6%, a decrease of 0.5 percentage points year-on-year, while the net profit margin was 64.7%, down 0.1 percentage points [4] - In Q4 2024, the gross margin was 94.0%, down 0.4 percentage points year-on-year, and the net profit margin was 57.2%, down 5.7 percentage points [4] R&D and Cost Management - The company increased its R&D investment, with a R&D expense ratio significantly rising, completing 57 patent applications and engaging in 21 collaborative research projects with medical institutions [4] - The overall expense ratio increased by 1.3 percentage points to 22.2%, driven by higher R&D costs, while sales expenses remained stable [4] Product Line Expansion - The company received a Class III medical device registration for a new gel product, expected to launch this year, which will enhance its gel product line [5] - Clinical trial approvals were obtained for several new products, indicating ongoing innovation and product development [5] Strategic Acquisition - The company plans to acquire REGEN Biotech, Inc. in March 2025, which is expected to strengthen its competitive advantage in the global regenerative market and enhance its overseas market expansion capabilities [7]